NBC news just reported on one of the newer technologies to diagnose Lyme disease, known as the Nanotrap test

NBC news just reported on one of the newer technologies to diagnose Lyme disease, known as the Nanotrap test. I discuss the Nanotrap test in my new book "How Can I Get Better?" in the context of a broad tick-borne testing panel. Here is an excerpt regarding testing strategies: "If you are doing testing for the first time, testing with a Lyme ELISA, or C6 ELISA, and IgM/IgG Western blot is generally a good idea, along with IgM and IgG Anaplasma/ Ehrlichia and Babesia testing, since these are the most commonly transmitted tick- borne infections (with Borrelia miyamotoi). If the ELISA is negative, perform a C6 ELISA, which is more sensitive. For the IgM and IgG Western blots, consider IGeneX laboratory in the United States, as it uses two strains of borrelia, the B-31 and 297 strains, which improves recognition of borrelia-specific bands versus using only the B-31 strain used by most commercial labs. Use other indirect tests such as the IFA and LTT (ELISPOT) if the above tests are indeterminate or negative, and consider antibody testing through Imugen for Borrelia miyamotoi, if it is available in your state. Direct testing using PCR for B. burgdorferi and B. miyamotoi, as well as the Lyme Dot Blot Assay (LDA), the Nanotrap test, and culture tests (Advanced Laboratory) can also be used...The Nanotrap test was published in 2015, as a new urine antigen test for detecting early stage Lyme and can also evaluate treatment. PCR's can also be performed on whole blood, serum, urine, breast milk, skin, and CSF, but due to the low numbers of bacteria usually present in specimens, samples can be negative and multiple tests may be necessary. TGen in Arizona is presently working on a newer generation PCR test to improve sensitivity". I will be at the Focus on Lyme conference in Arizona, February 23 & 24, 2017, discussing newer testing and treatment regimens, where Paul Keim from TGen will be present to discuss his updates on LymeSeq 2.0. I hope to see you there.